期刊文献+

4-异丁氧基苄胺的合成 被引量:1

Synthesis of 4-Isobutoxybenzylamine
下载PDF
导出
摘要 对羟基苯甲醛和异丁基溴为起始原料经过取代、正向肟化、加氢等合成4-异丁氧基苄胺。对羟基苯甲醛与异丁基溴按摩尔比为1∶2,反应温度为90℃,时间为9h合成4-异丁氧基苯甲醛;4-异丁氧基苯甲醛与盐酸羟胺的摩尔比为1∶2,反应温度为102℃,反应时间为40 h,合成4-异丁氧基苯甲醛肟;4-异丁氧基苯甲醛肟加氢反应在100℃,反应15h合成4-异丁氧基苄胺,4-异丁氧基苄胺总收率达到64%。 4-Isobutoxybenzylamine was synthesized from p-hydroxybenzaldehyde and isobutyl bromide via substitution,forward oxime and hydrogenation.Firstly 4-isobutoxybenzaldehyde was prepared when the molar ratio of p-hydroxybenzaldehyde to isobutyl bromide was 1∶2,the reaction temperature was 90℃a nd the reaction time was 9 h.And then 4-isobutoxybenzaldehyde oxime was prepared when the molar ratio of 4-isobutoxybenzaldehyde to hydroxylamine hydrochloride was 1∶2,the reaction temperature was 102℃,the reaction time was 40 h.At last,4-isobutoxybenzylamine was obtained through the hydrogenation reaction of 4-isobutoxybenzaldehyde oxime for 15 h at 100℃,and the reaction yield reached 64%.
作者 李颖 牟旭 迭杉杉 代文双 LI Ying;MU Xu;DIE Shan-shan;DAI Wen-shuang(School of Biomedical and Chemical Engineering,Liaoning Institute of Science and Technology,Liaoning Benxi 117004,China;Sichuang Zhongke Huizhi Petroleum Engineering Design Co.,Ltd.,Sichuan Chengdu 610066,China)
出处 《辽宁化工》 CAS 2020年第4期344-345,350,共3页 Liaoning Chemical Industry
基金 辽宁省教育厅科学技术研究项目(201710311) 辽宁科技学院大学生创新训练项目(201911430019)。
关键词 4-异丁氧基苄胺 对羟基苯甲醛 异丁基溴 合成 4-isobutoxybenzylamine p-hydroxybenzaldehyde isobutyl bromine synthesis
  • 相关文献

参考文献6

二级参考文献27

  • 1Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality[J]. Neurology, 1967, 17(5) : 427-442.
  • 2Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinson- ism in humans due to a product of meperidine-analog synthesis [J]. Science, 1983, 219(4587) : 979-980.
  • 3Chou KL, Borek LL, Friedman JH. The management of psycho- sis in movement disorder patients [J ] er, 2007, 8(7): 935-943.
  • 4Expert Opin Pharmacoth- Grohmann R, Rather E, Sassim N, et al. Adverse effects of clo-zapine[J]. Psychopharmacology (Berl), 1989, 99(1): S101- S104.
  • 5Molho ES, Factor SA. Worsening of motor features of parkinson- ism with olanzapine[J]. Mov Disord, 1999, 14(6) : 1014-1016.
  • 6Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis [J]. Neuropsychopharmacology, 2010, 35 (4) : 881-892.
  • 7Thygesen M, Schlienger N, Tolf BR, et al. Process for prepara- tion of salts of N- (4-fluorobenzyl) -N- ( 1 -methylpiperidin-4-yl) - N'- (4- (2-methylpropyloxy) phenylmethyl) carbamide: WO, 2006036874[P]. 2006-04-06.
  • 8Gant G, Sarshar S. Substituted ureas as 5-HT receptor modula- tors and their preparation and use in the treatment of diseases : US, 20080280886[P]. 2008-11-03.
  • 9Andersson CM, Croston C, Hansen EL, et al. Azacyclic com- pounds for use in the treatment of serotonin related diseases: WO, 2001066521 [ P]. 2001-09-13.
  • 10Mills R, Williams HL. Methods for the treatment of Parkinson's disease psychosis using pimavansem: WO 2014085362 A1 [P]. 2014-06-05.

共引文献14

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部